MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
Organization & Developments: Ligand
Parents
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
Children
*Cancer and pain drugs
*If R&D yields commercial drugs, they will get 4% to 5% in royalties.
*Ligand essentially passes off the heavy lifting needed to bring drugs to market, enjoying royalties and milestones with relatively little investment costs.
*Ligand has more than 140 partnered programs with over 70 different companies.
*Novel business model, designed to thrive in today's pharmaceutical industry, is guided by the following principles: • We focus primarily on drug discovery and let our partners do the rest • We maintain a very large portfolio of assets to diversify
2008: Ligand Cuts Another Deal With GlaxoSmithKline (2008)
2010: Roche Ends Deal with Ligand (2010)
2016: Biotech Daily Digest: A Buyout For Biogen? The Rally Continues. Spotlight On Ligand Pharmaceuticals
2016: Ligand Pharma Adds Tech, Grows On Partners’ Success
2019: Ligand Pharmaceuticals stock down after extremely critical Citron report
2020: Ligand: Scalable Growth
2021: One Of The Most Shorted Names In Biotech: Ligand Pharmaceuticals
2021: Ligand's Ailing Remdesivir Cash Cow
2022: Ligand Pharmaceuticals (LGND) Investor Presentation - Slideshow _ seekingalpha.com
2024: Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
2024: Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
2024: Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies
2024: Ligand Pharmaceuticals' SWOT analysis: stock's growth potential in focus
2024: Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
2025: Ligand Pharmaceuticals sees 22% CAGR in royalty revenue through 2029
2025: Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward
2025: Looking Back On Ligand Pharmaceuticals
Jumps
*Key People: Ligand
Finance & Acquisitions: Ligand